Advert - Organon – Case/0262/08/24

For promoting Nexplanon (etonogestrel) outside its marketing authorisation, by implying it was a suitable option for preventing all ages of teenage pregnancy when efficacy and safety had not been established in women under 18 years of age, Organon was ruled in breach of the following clauses of the 2021 Code:

 

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1        - Failing to maintain high standards

Clause 11.2      - Promoting a medicine outside the terms of its marketing authorisation

Advert 24 October 2025